Avinger Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer
Avinger (Nasdaq: AVGR) has appointed Thomas P. Davis, MD, FACC as Chief Medical Officer for its peripheral business. Dr. Davis, a highly experienced interventional cardiologist and key opinion leader in peripheral vascular space, brings over three decades of expertise to the role. He will work closely with the executive team on clinical strategy and medical affairs initiatives to drive adoption of Avinger's image-guided therapies and foster collaboration with the medical community.
Dr. Davis is a practicing interventional cardiologist focused on peripheral artery disease and non-surgical limb salvage. He also serves as Director of Cardiovascular Research at St. John Hospital and Medical Center in Detroit, Michigan. As a long-time user of Avinger technology, Dr. Davis has witnessed the clinical benefits of real-time image-guidance in terms of safety and long-term efficacy.
Avinger (Nasdaq: AVGR) ha nominato Thomas P. Davis, MD, FACC come Chief Medical Officer per il suo business periferico. Il Dr. Davis, un cardiologo interventista di grande esperienza e leader di opinione nel campo vascolare periferico, porta con sé oltre tre decenni di esperienza nel ruolo. Lavorerà a stretto contatto con il team esecutivo su strategia clinica e iniziative di affari medici per promuovere l'adozione delle terapie guidate da immagini di Avinger e favorire la collaborazione con la comunità medica.
Il Dr. Davis è un cardiologo interventista attivo, specializzato nella malattia arteriosa periferica e nel salvataggio degli arti senza intervento chirurgico. È anche Direttore della Ricerca Cardiovascolare presso il St. John Hospital e Medical Center di Detroit, Michigan. In quanto utilizzatore di lunga data della tecnologia Avinger, il Dr. Davis ha potuto osservare i benefici clinici della guida delle immagini in tempo reale in termini di sicurezza ed efficacia a lungo termine.
Avinger (Nasdaq: AVGR) ha nombrado a Thomas P. Davis, MD, FACC como Director Médico para su negocio periférico. El Dr. Davis, un cardiologo intervencionista altamente experimentado y líder de opinión clave en el espacio vascular periférico, aporta más de tres décadas de experiencia al puesto. Trabajará en estrecha colaboración con el equipo ejecutivo en estrategia clínica e iniciativas de asuntos médicos para impulsar la adopción de las terapias guiadas por imágenes de Avinger y fomentar la colaboración con la comunidad médica.
El Dr. Davis es un cardiologo intervencionista en ejercicio, enfocado en la enfermedad arterial periférica y el salvamento de extremidades sin cirugía. También se desempeña como Director de Investigación Cardiovascular en el St. John Hospital y Medical Center en Detroit, Michigan. Como usuario de largo tiempo de la tecnología de Avinger, el Dr. Davis ha sido testigo de los beneficios clínicos de la guía por imágenes en tiempo real en términos de seguridad y eficacia a largo plazo.
Avinger (Nasdaq: AVGR)는 Thomas P. Davis, MD, FACC를 말초 사업부의 최고 의료 책임자로 임명했습니다. Davis 박사는 매우 경험이 풍부한 중재 심장전문의이자 말초 혈관 분야의 주요 의견 리더로서, 이 역할에 30년이 넘는 전문성을 제공합니다. 그는 임상 전략 및 의료업무 이니셔티브에 대해 경영진 팀과 긴밀히 협력하여 Avinger의 영상 유도 요법의 채택을 촉진하고 의료 커뮤니티와의 협력을 강화할 것입니다.
Davis 박사는 말초 동맥 질환과 비수술적 사지 구제에 집중하는 중재 심장전문의로 활동하고 있습니다. 그는 또한 미시건주 디트로이트에 있는 St. John Hospital and Medical Center의 심혈관 연구 본부장입니다. Avinger 기술의 장기 사용자인 Davis 박사는 안전성과 장기 효능 측면에서 실시간 영상 유도의 임상적 이점을 경험해왔습니다.
Avinger (Nasdaq: AVGR) a nommé Thomas P. Davis, MD, FACC en tant que Directeur Médical pour son activité périphérique. Le Dr Davis, cardiologue interventionnel très expérimenté et leader d'opinion clé dans le domaine vasculaire périphérique, apporte plus de trois décennies d'expertise à ce poste. Il travaillera en étroite collaboration avec l'équipe dirigeante sur la stratégie clinique et des initiatives en affaires médicales pour favoriser l'adoption des thérapies guidées par imagerie d'Avinger et encourager la collaboration avec la communauté médicale.
Le Dr Davis est un cardiologue interventionnel en exercice, spécialisé dans la maladie artérielle périphérique et la préservation des membres sans intervention chirurgicale. Il est également directeur de la recherche cardiovasculaire au St. John Hospital et Medical Center à Detroit, dans le Michigan. En tant qu'utilisateur de longue date de la technologie d'Avinger, le Dr Davis a été témoin des bénéfices cliniques de la guidance par imagerie en temps réel en termes de sécurité et d'efficacité à long terme.
Avinger (Nasdaq: AVGR) hat Thomas P. Davis, MD, FACC als Chief Medical Officer für sein peripheres Geschäft ernannt. Dr. Davis, ein sehr erfahrener interventioneller Kardiologe und Meinungsführer im Bereich der peripheren Gefäße, bringt über drei Jahrzehnte Erfahrung in diese Rolle ein. Er wird eng mit dem Führungsteam an klinischen Strategien und medizinischen Initiativen arbeiten, um die Akzeptanz von Avingers bildgeführten Therapien voranzutreiben und die Zusammenarbeit mit der medizinischen Gemeinschaft zu fördern.
Dr. Davis ist ein praktizierender interventioneller Kardiologe, der sich auf periphere Arterienerkrankungen und nicht-chirurgische Gliedmaßenrettung spezialisiert hat. Außerdem ist er Direktor der Herz-Kreislauf-Forschung im St. John Hospital und Medical Center in Detroit, Michigan. Als langjähriger Nutzer der Avinger-Technologie hat Dr. Davis die klinischen Vorteile der Echtzeitbildführung hinsichtlich Sicherheit und langfristiger Wirksamkeit erlebt.
- Appointment of a highly experienced and respected medical professional as Chief Medical Officer
- Potential for increased adoption of Avinger's image-guided therapies due to Dr. Davis' expertise and influence
- Enhanced clinical strategy and medical affairs initiatives expected from the new appointment
- Strengthened leadership team with addition of a key opinion leader in the peripheral vascular space
- None.
REDWOOD CITY, CA / ACCESSWIRE / August 5, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the appointment of Thomas P. Davis, MD, FACC, as Chief Medical Officer for its peripheral business. As a highly experienced interventional cardiologist and key opinion leader (KOL) in the peripheral vascular space, Dr. Davis has operated at the forefront of medical device innovation and advancing patient care in a career spanning more than three decades. Dr. Davis has pioneered the use of several cutting-edge interventional technologies to treat vascular disease, including Avinger's proprietary image-guided CTO-crossing and atherectomy catheters.
As Chief Medical Officer, Dr. Davis will work closely with the executive team on clinical strategy and medical affairs initiatives to drive adoption of Avinger's image-guided therapies and foster collaboration with the broader medical community. In addition to his new role as Chief Medical Officer at Avinger, Dr. Davis is a practicing interventional cardiologist focused on peripheral artery disease and non-surgical limb salvage. He also serves as Director of Cardiovascular Research at St. John Hospital and Medical Center in Detroit, Michigan and previously had the leadership role of Director of the Cardiac Catheterization Lab and Director of Peripheral Interventions at the same institution. Dr. Davis has served on several scientific advisory boards for interventional device development and has participated as an investigator in multiple clinical trials for new endovascular technologies, including several Avinger studies. He has authored numerous publications and conducted groundbreaking research that has significantly influenced the treatment and outcomes of patients suffering from peripheral vascular disease, as well as serving as faculty at several national conferences.
"We are excited to welcome Dr. Davis to our leadership team. As one of the preeminent leaders in the peripheral interventional space, and an expert operator of Avinger's image-guided technologies in hundreds of procedures, Dr. Davis will provide unparalleled clinical expertise and strategic insights to this role," commented Jeff Soinski, president and CEO of Avinger. "We expect that he will make significant contributions to our ongoing product development and launch activities, advance the awareness of our best-in-class data for in-stent restenosis and below-the-knee treatment, and significantly contribute to the adoption of image-guided technology within the interventional community."
Dr. Davis added, "I am thrilled to take on this role, and look forward to driving awareness amongst my fellow interventionists about the multitude of benefits this technology offers both physicians and their patients. As a long-time user of Avinger technology, I have witnessed firsthand the outstanding and reproducible clinical outcomes that real-time image-guidance provides, both in terms of safety and long-term efficacy. With the most advanced products for treating vascular disease in the clinic, and excellent clinical data to support their use for many types of peripheral interventions, Avinger's OCT-guided portfolio offers a new standard of care."
Avinger's proprietary technology incorporates an onboard image-guidance system to allow physicians to see inside the artery during an atherectomy or CTO-crossing procedure by using an imaging modality called optical coherence tomography, or OCT. During the procedure, high-resolution intravascular OCT images are displayed on Avinger's Lightbox console in real-time to guide therapy. Physicians performing therapeutic procedures with other devices must rely solely on X-ray images and tactile feedback to guide their interventions while treating complicated arterial disease. With Avinger's unique approach, physicians can more accurately navigate their devices and treat PAD lesions to deliver safe and effective outcomes, without exposing healthcare workers and patients to the negative effects of ionizing radiation.
About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first image-guided, catheter-based system for the diagnosis and treatment of patients with vascular disease in the peripheral and coronary arteries. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox series of imaging consoles, the Ocelot and Tigereye® family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices for the treatment of peripheral artery disease (PAD), estimated to affect more than 200 million people worldwide. Avinger is developing its first product application for the treatment of coronary artery disease (CAD), an image-guided system for CTO-crossing in the coronary arteries, which provides the opportunity to redefine a large and underserved market. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.
Follow Avinger on Twitter and Facebook.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the anticipated benefits and adoption of our products. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include the resource requirements related to our products; the timing and outcome of studies; as well as the other risks described in the section entitled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2024, as amended, and Quarterly Report on Form 10-Q. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Avinger disclaims any obligation to update these forward-looking statements.
Investor Contact:
Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com
Public Relations Contact:
Phil Preuss
Chief Commercial Officer
Avinger, Inc.
(650) 241-7900
pr@avinger.com
SOURCE: Avinger, Inc.
View the original press release on accesswire.com
FAQ
Who is the new Chief Medical Officer of Avinger (AVGR)?
What is Dr. Thomas P. Davis' background and experience relevant to Avinger (AVGR)?
How might Dr. Davis' appointment impact Avinger's (AVGR) business?
What is unique about Avinger's (AVGR) technology in vascular disease treatment?
